Literature DB >> 22915161

New tools for assessing the individual risk of metastasis in renal cell carcinoma.

Edwin Herrmann1, Carsten Weishaupt, Birgit Pöppelmann, Carina Hillgruber, Gerald Pühse, Laura Maria Krabbe, Micha Feld, Martin Steinhoff, Tobias Goerge.   

Abstract

Localized renal cell carcinoma (RCC) progresses to metastatic disease in 20-40 % after surgical resection. Affected patients might benefit from adjuvant treatment and have to be reliably identified for treatment indication. However, existing molecular markers and classification nomograms lack sufficient validity for clinical application so far. Therefore, in order to improve diagnostic tools for the identification of patients at risk, we tested invasiveness and the capability to activate vascular endothelium of primary RCC cells as tumor specific functional parameters. As a parameter for cell invasiveness the ability of RCC cells to break-down transepithelial electrical resistance (TEER) of an epithelial cell monolayer was tested. Loss of resistance, calculated as invasivity index, resembled the degree of cell invasiveness. In addition, secretion of Von Willebrand Factor by endothelial cells incubated with RCC cell supernatant was measured as a surrogate marker for endothelial cell activation. TEER-assay results matched clinical status of disease in 9 out of 12 cases. Metastatic tumors and less differentiated tumors had a significant increase of invasivity index (p = 0.007; p = 0.034). Endothelial cell activation and clinical outcome matched in 5 out of 9 samples. In addition, tumor cell induced endothelial cell activation significantly correlated to the pathologic T classification status of RCC tumors (p = 0.009). Taken together, our study validated endothelial cell activation analysis and cell invasiveness as solitary prognostic markers for tumor dissemination. TEER-analysis has proven to be a useful functional assay giving highly relevant individual information on functional tumor cell characteristics that add to pathologic evaluation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22915161     DOI: 10.1007/s10585-012-9529-6

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  37 in total

1.  High-resistance MDCK-C7 monolayers used for measuring invasive potency of tumour cells.

Authors:  J Zak; S W Schneider; I Eue; T Ludwig; H Oberleithner
Journal:  Pflugers Arch       Date:  2000-05       Impact factor: 3.657

2.  Strong significant correlation between MMP-9 and systemic symptoms in patients with localized renal cell carcinoma.

Authors:  Nozomu Kawata; Yusuke Nagane; Takumi Igarashi; Hitoshi Hirakata; Taketo Ichinose; Takahiko Hachiya; Yukie Takimoto; Satoru Takahashi
Journal:  Urology       Date:  2006-09-18       Impact factor: 2.649

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

Review 4.  Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.

Authors:  Krisztian Homicsko; Dominik R Berthold
Journal:  Anticancer Drugs       Date:  2011-01       Impact factor: 2.248

5.  Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study.

Authors:  Vladimir V Iakovlev; Manal Gabril; William Dubinski; Andreas Scorilas; Youssef M Youssef; Hala Faragalla; Kalman Kovacs; Fabio Rotondo; Shereen Metias; Androu Arsanious; Anna Plotkin; Andrew H F Girgis; Catherine J Streutker; George M Yousef
Journal:  Lab Invest       Date:  2011-10-31       Impact factor: 5.662

6.  Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion.

Authors:  Eva-Maria Schnaeker; Rainer Ossig; Thomas Ludwig; Rita Dreier; Hans Oberleithner; M Wilhelmi; Stefan W Schneider
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

7.  Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

Authors:  Michael Atkins; Meredith Regan; David McDermott; James Mier; Eric Stanbridge; Amanda Youmans; Philip Febbo; Melissa Upton; Mirna Lechpammer; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

8.  Functional measurement of local proteolytic activity in living cells of invasive and non-invasive tumors.

Authors:  Thomas Ludwig; Sylvia Püttmann; Helga Bertram; Lars Tatenhorst; Werner Paulus; Hans Oberleithner; Volker Senner
Journal:  J Cell Physiol       Date:  2005-03       Impact factor: 6.384

9.  Microfluidic reveals generation of platelet-strings on tumor-activated endothelium.

Authors:  Tobias Goerge; Felix Kleinerüschkamp; Alexej Barg; Eva-Maria Schnaeker; Volker Huck; Matthias F Schneider; Martin Steinhoff; Stefan W Schneider
Journal:  Thromb Haemost       Date:  2007-08       Impact factor: 5.249

Review 10.  Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability.

Authors:  Christian Eichelberg; Kerstin Junker; Börje Ljungberg; Holger Moch
Journal:  Eur Urol       Date:  2009-01-13       Impact factor: 20.096

View more
  3 in total

1.  Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.

Authors:  Daniel Keizman; David Sarid; Jae L Lee; Avishay Sella; Maya Gottfried; Hans Hammers; Mario A Eisenberger; Michael A Carducci; Victoria Sinibaldi; Victoria Neiman; Eli Rosenbaum; Avivit Peer; Avivit Neumann; Wilmosh Mermershtain; Keren Rouvinov; Raanan Berger; Ibrahim Yildiz
Journal:  Oncologist       Date:  2016-07-05

2.  Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.

Authors:  Anna Maria Trotta; Sara Santagata; Serena Zanotta; Crescenzo D'Alterio; Maria Napolitano; Giuseppina Rea; Rosa Camerlingo; Fabio Esposito; Elvira Lamantia; Annamaria Anniciello; Giovanni Botti; Nicola Longo; Gerardo Botti; Sandro Pignata; Sisto Perdonà; Stefania Scala
Journal:  J Exp Clin Cancer Res       Date:  2018-12-04

3.  Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?

Authors:  Daniel Keizman; Keren Rouvinov; Avishay Sella; Maya Gottfried; Natalie Maimon; Jenny J Kim; Mario A Eisenberger; Victoria Sinibaldi; Avivit Peer; Michael A Carducci; Wilmosh Mermershtain; Raya Leibowitz-Amit; Rony Weitzen; Raanan Berger
Journal:  Cancer Res Treat       Date:  2015-03-05       Impact factor: 4.679

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.